Evercore ISI Downgrades Upstream Bio to In Line, Slashes Price Target to $15

Evercore ISI has downgraded Upstream Bio (UPB) from Outperform to In Line, significantly reducing its price target from $40 to $15. Analysts cited a lack of meaningful catalysts over the next 12 months and ongoing uncertainties regarding financing as primary drivers for the downgrade. In a move to address these capital concerns, Upstream Bio recently established a $150 million at-the-market (ATM) equity program through Leerink Partners LLC. This program allows the company to sell common stock flexibly based on market conditions, with a commission of up to 3.0% for the sales agent. Additionally, challenges related to dosing in the company's COPD clinical trials have weighed on analyst sentiment. Shares of Upstream Bio had previously fallen by more than 6% in response to the downgrade, reflecting a cautious stance on the firm's ability to navigate current operational and financial headwinds.

Sources:Financial Modeling Prepbenzinga.commarketbeat.cominvesting.comstreetinsider.com247wallst.comtipranks.comStock Titan